Giverny Capital’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-257
| Closed | -$19K | – | 56 |
|
|
2024
Q4 | $19K | Sell |
257
-446,031
| -100% | -$31.2M | ﹤0.01% | 62 |
|
|
2024
Q3 | $29.5M | Buy |
446,288
+272
| +0.1% | +$19.8K | 1.12% | 28 |
|
|
2024
Q2 | $41.2M | Buy |
446,016
+298
| +0.1% | +$26.4K | 1.74% | 23 |
|
|
2024
Q1 | $42.6M | Buy |
445,718
+4,812
| +1% | +$404K | 1.73% | 21 |
|
|
2023
Q4 | $33.6M | Buy |
440,906
+304
| +0.1% | +$21.2K | 1.58% | 23 |
|
|
2023
Q3 | $30.5M | Buy |
440,602
+706
| +0.2% | +$56.7K | 1.66% | 21 |
|
|
2023
Q2 | $41.5M | Buy |
439,896
+24,921
| +6% | +$2.17M | 2.18% | 18 |
|
|
2023
Q1 | $34.3M | Sell |
414,975
-11,198
| -3% | -$880K | 2.07% | 19 |
|
|
2022
Q4 | $31.8M | Sell |
426,173
-4,023
| -0.9% | -$310K | 1.97% | 19 |
|
|
2022
Q3 | $35.5M | Buy |
430,196
+13,314
| +3% | +$1.28M | 2.41% | 15 |
|
|
2022
Q2 | $39.6M | Buy |
416,882
+11,791
| +3% | +$1.22M | 2.61% | 16 |
|
|
2022
Q1 | $47.7M | Sell |
405,091
-671
| -0.2% | -$75.3K | 2.69% | 16 |
|
|
2021
Q4 | $52.6M | Buy |
405,762
+3,612
| +0.9% | +$421K | 2.8% | 15 |
|
|
2021
Q3 | $45.5M | Sell |
402,150
-3,379
| -0.8% | -$386K | 2.71% | 17 |
|
|
2021
Q2 | $42M | Buy |
405,529
+15,389
| +4% | +$1.45M | 2.55% | 17 |
|
|
2021
Q1 | $32.6M | Buy |
390,140
+2,326
| +0.6% | +$197K | 2.18% | 19 |
|
|
2020
Q4 | $35.4M | Buy |
387,814
+14,392
| +4% | +$1.19M | 2.71% | 17 |
|
|
2020
Q3 | $29.8M | Buy |
373,422
+795
| +0.2% | +$62K | 2.73% | 17 |
|
|
2020
Q2 | $25.8M | Buy |
372,627
+17,349
| +5% | +$1.23M | 2.56% | 17 |
|
|
2020
Q1 | $22.3M | Sell |
355,278
-30,267
| -8% | -$2.18M | 2.84% | 15 |
|
|
2019
Q4 | $30M | Buy |
385,545
+3,846
| +1% | +$300K | 2.71% | 16 |
|
|
2019
Q3 | $28M | Buy |
381,699
+729
| +0.2% | +$51.2K | 2.79% | 14 |
|
|
2019
Q2 | $23.5M | Buy |
380,970
+9,201
| +2% | +$556K | 2.37% | 18 |
|
|
2019
Q1 | $23.7M | Buy |
371,769
+5,235
| +1% | +$299K | 2.72% | 15 |
|
|
2018
Q4 | $18.7M | Sell |
366,534
-175,536
| -32% | -$8.88M | 2.47% | 16 |
|
|
2018
Q3 | $31.5M | Buy |
542,070
+24,546
| +5% | +$1.2M | 3.56% | 11 |
|
|
2018
Q2 | $25.1M | Buy |
517,524
+4,026
| +0.8% | +$188K | 3.27% | 12 |
|
|
2018
Q1 | $23.9M | Buy |
513,498
+28,785
| +6% | +$1.25M | 3.2% | 13 |
|
|
2017
Q4 | $18.2M | Buy |
+484,713
| New | +$17.8M | 2.5% | 19 |
|
Other funds holding EW
Giverny Capital's EW Position: Q1 2025 in Review
Giverny Capital sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 257 shares — an estimated $19K sold.
Giverny Capital first reported a position in EW in Q4 2017 and held it in 29 quarters. The position peaked at $52.6M in Q4 2021. 1,205 funds tracked by Wall St. Rank hold EW as of Q1 2025.
- Giverny Capital reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
- Giverny Capital sold 257 Edwards Lifesciences shares in Q1 2025, an estimated $19K.
- Giverny Capital first reported a position in Edwards Lifesciences in Q4 2017 and held it in 29 quarters.
- Giverny Capital's Edwards Lifesciences position peaked at $52.6M in Q4 2021.
- 1,205 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.
Based on Giverny Capital's 13F filing for Q1 2025, filed 13 May 2025.